What’s the current market cap for Dyne Therapeutics stock?

Dyne Therapeutics (DYN) has a market cap of $3bn as of June 17, 2026.

What is the P/E ratio for Dyne Therapeutics stock?

The price to earnings (P/E) ratio for Dyne Therapeutics (DYN) stock is 0 as of June 17, 2026.

Does Dyne Therapeutics stock pay dividends?

No, Dyne Therapeutics (DYN) stock does not pay dividends to its shareholders as of June 17, 2026.

When is the next Dyne Therapeutics dividend payment date?

Dyne Therapeutics (DYN) stock does not pay dividends to its shareholders.

What is the beta indicator for Dyne Therapeutics?

Dyne Therapeutics (DYN) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Dyne Therapeutics stock | $DYN Share Price

13:30

15:10

16:45

18:25

20:00

About Dyne Therapeutics

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Ticker

$DYN

Sector

Health

Primary listing

NASDAQ

Employees

263

Headquarters

Waltham, United States

Website

www.dyne-tx.com

DYN Metrics

BasicAdvanced

$3bn

-$3.18

1.08

What the Analysts think about DYN

Analyst ratings (Buy, Hold, Sell) for Dyne Therapeutics stock.

Bulls say / Bears say

As of December 31, 2025, Dyne ended the year with approximately $1.1 billion in cash, cash equivalents, and marketable securities, securing its cash runway into Q1 2028 and reducing near-term financing risk. (Reuters via SahmCapital)

The FDA granted Breakthrough Therapy Designation to DYNE-251 (zeleciment rostudirsen) for Duchenne muscular dystrophy, potentially expediting clinical development and regulatory approval. (Reuters)

Dyne secured a $50 million tranche under its amended Hercules Capital debt facility, with access to up to $75 million more contingent on clinical and regulatory milestones, bolstering its financial flexibility. (Reuters)

Dyne reported a Q4 2025 net loss of $112 million and a full-year loss of $446 million, with R&D expenses of $398 million, underscoring substantial cash burn. (Reuters via SahmCapital)

The pivotal Phase 3 FORZETTO trial for z-rostudirsen only commenced in Q2 2026, delaying confirmatory data readouts and increasing binary event risk before a potential approval. (Reuters via SahmCapital)

Debt obligations under the Hercules Capital facility include covenants tied to clinical and regulatory milestones, risking funding suspension or default if key targets are not met. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 2 Jun 2026.

DYN Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

DYN Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DYN

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

The FDA granted Breakthrough Therapy Designation to DYNE-251 (zeleciment rostudirsen) for Duchenne muscular dystrophy, potentially expediting clinical development and regulatory approval. (Reuters)

Dyne reported a Q4 2025 net loss of $112 million and a full-year loss of $446 million, with R&D expenses of $398 million, underscoring substantial cash burn. (Reuters via SahmCapital)

Debt obligations under the Hercules Capital facility include covenants tied to clinical and regulatory milestones, risking funding suspension or default if key targets are not met. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 2 Jun 2026.

About Dyne Therapeutics

Ticker

Employees

DYN Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about DYN

Analyst Ratings

Bulls say / Bears say

DYN Financial Performance

Income Statement

DYN Earnings Performance

Earnings per share (EPS)

Buy $DYN

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Dyne Therapeutics/$DYN

About Dyne Therapeutics

Ticker

Employees

DYN Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about DYN

Analyst Ratings

Bulls say / Bears say

DYN Financial Performance

Income Statement

DYN Earnings Performance

Earnings per share (EPS)

Buy $DYN

Upcoming events

No upcoming events

What’s the current market cap for Dyne Therapeutics stock?

What is the P/E ratio for Dyne Therapeutics stock?

Does Dyne Therapeutics stock pay dividends?

When is the next Dyne Therapeutics dividend payment date?

What is the beta indicator for Dyne Therapeutics?

Bulls say / Bears say